Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently presented data from its ongoing trial during the San Antonio Breast Cancer Symposium (“SABCS”), one of the largest breast cancer conferences in the world. An article discussing the company reads, “The December 6 conference poster session presentation showed safety and efficacy results of BriaCell’s phase I/IIa targeted immunotherapy trial in patients with advanced breast cancer, as well as the early safety data of the combination study of Bria-IMT™ with KEYTRUDA®. KEYTRUDA® targets protein PD-1, which can block immune system cells from fighting off tumor cells. KEYTRUDA® attempts to “release the brakes” set in place by PD-1 and let the immune system do its work. BriaCell believes that the combination of Bria-IMT™ with KEYTRUDA® will be much more effective in killing the tumor cells compared with using either of the drugs alone.”
To view the full article, visit http://nnw.fm/SBm1s
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com